LCAT has been reported as a prognostic and recurrence biomarker in HCC (Long et al., 2019; Hu et al., 2020; Jiang et al., 2020; Su et al., 2021; Sharifi et al., 2022) and has been correlated to anti-cancer drug sensitivities (Zhang et al., 2022). This evidence concerns the gene LCAT and hepatocellular carcinoma.